Suppr超能文献

乳腺癌中禁止素-I的组织表达及其与预后因素的关系。

Tissue Expression of Prohibition-I and It's Relationship With Prognostic Factors in Breast Cancer.

作者信息

Javid Hossein, Hashemy Isaac, Shahidsales Soudabeh, Mohammadian Roshan Nema, Kianoosh Tayebeh, Zahedi Avval Farnaz

机构信息

Dept. of Clinical Biochemistry, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.

出版信息

Iran J Pathol. 2018 Spring;13(2):237-244. Epub 2018 Jul 17.

Abstract

BACKGROUND & OBJECTIVE: Globally, breast cancer is the most common malignancy among females. Prohibition (PHB)-I, a homologous protein, was initially introduced as a suppressor gene for amplification process. Further, the protein has a key role in the cell cycle and is capable of inhibiting DNA transcription in many cell types. Therefore, its possible role in different types of human malignancies is of interest.The current study aimed at examining the relationship between the tissue distribution of PHB-I and prognostic factors of breast cancer.

METHODS

Paraffin-embedded tissue specimens of 33 patients diagnosed with breast cancer at Omid teaching Hospital, Mashhad, Iran were studied and a commercial monoclonal antibody was used to perform immunohistochemistry (IHC). The relationship between PHB-I tissue expression with age, disease stage, tumor grade and size, as well as hormone receptor status including estrogen (ER) and progesterone (PR) receptors, and Her-2 receptor were evaluated.

RESULTS

The Immunohistochemical analysis showed a relative increase in PHB-I tissue expression along with higher tumor grade (=0.057). In addition, higher expression of ER and PR were observed (=0.027 and 0.009, respectively). The age of patients and other prognostic factors including Her-2 receptor status and disease stage did not statistically correlate with PHB-I expression.

CONCLUSION

An increased expression of PHB-I was observed in the breast cancer tumors of the current study patients compared with the anatomically healthy margin. Its coloration with some prognostic factors such as disease grade and expression of ER and PR might indicate the PHB-I potential application for diagnostic and patient management purposes.

摘要

背景与目的

在全球范围内,乳腺癌是女性中最常见的恶性肿瘤。禁止蛋白(PHB)-I是一种同源蛋白,最初作为扩增过程的抑制基因被引入。此外,该蛋白在细胞周期中起关键作用,并且能够在多种细胞类型中抑制DNA转录。因此,其在不同类型人类恶性肿瘤中的潜在作用备受关注。本研究旨在探讨PHB-I的组织分布与乳腺癌预后因素之间的关系。

方法

对伊朗马什哈德奥米德教学医院诊断为乳腺癌的33例患者的石蜡包埋组织标本进行研究,并使用一种商业单克隆抗体进行免疫组织化学(IHC)检测。评估PHB-I组织表达与年龄、疾病分期、肿瘤分级和大小,以及激素受体状态(包括雌激素(ER)和孕激素(PR)受体)和Her-2受体之间的关系。

结果

免疫组织化学分析显示,随着肿瘤分级升高,PHB-I组织表达相对增加(=0.057)。此外,还观察到ER和PR表达较高(分别为=0.027和0.009)。患者年龄和其他预后因素,包括Her-2受体状态和疾病分期,与PHB-I表达无统计学相关性。

结论

与解剖学上健康的边缘组织相比,本研究患者的乳腺癌肿瘤中观察到PHB-I表达增加。其与一些预后因素(如疾病分级以及ER和PR的表达)的关联可能表明PHB-I在诊断和患者管理方面的潜在应用价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8127/6339505/6cb97ba0ea55/ijp-13-237-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验